An Intracellular Enzyme Drug via Endocytosis: Olipudase Alfa (Xenpozyme)
In August 2022, olipudase alfa (Xenpozyme), a hydrolytic lysosomal sphingomyelin-specific enzyme indicated for non–CNS manifestations of acid sphingomyelinase deficiency (ASMD), was approved in the US and Europe.
This Premium deep dive into Xenpozyme includes:
the industry context,
the clinical data,
the target rationale,
the mechanism of action,
and the drug’s origins.
Loading...